Johnson & Johnson (JNJ) EV/Assets Ratio: 3.10x
Is Johnson & Johnson’s EV/Assets ratio high or low?
Johnson & Johnson's EV/Assets ratio of 3.10x is 25% above its 5-year average of 2.49x, near the high end of its 5-year range (1.90x–3.18x).
As of Monday, June 15, 2026. 15.67% above its 12-month average of 2.68x.
JNJ EV/Assets Ratio Chart
JNJ Average EV/Assets Ratio Chart
JNJ Current vs Average EV/Assets Ratio Chart
JNJ EV/Assets Ratio Metrics
EV/ASSETS RATIO
3.10x
EV/ASSETS RATIO AVG TTM
2.68x
EV/ASSETS RATIO AVG 3Y
2.33x
EV/ASSETS RATIO AVG 5Y
2.49x
EV/ASSETS RATIO AVG 10Y
2.48x
EV/ASSETS RATIO AVG 15Y
2.34x
EV/ASSETS RATIO AVG 20Y
2.29x
CURRENT VS TTM AVG
+15.67%
CURRENT VS 3Y AVG
+33.21%
CURRENT VS 5Y AVG
+24.57%
CURRENT VS 10Y AVG
+24.93%
CURRENT VS 15Y AVG
+32.35%
CURRENT VS 20Y AVG
+35.67%
JNJ Competitors' EV/Assets Ratio
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Johnson & Johnson (JNJ) | $579.83B | 3.10x | 2.68x | 2.33x | 2.49x |
| Pfizer Inc. (PFE)vs › | $149.38B | 1.03x | 1.00x | 1.03x | 1.28x |
| Merck & Co., Inc. (MRK)vs › | $294.03B | 2.63x | 2.21x | 2.57x | 2.53x |
| AbbVie Inc. (ABBV)vs › | $402.35B | 3.43x | 3.29x | 2.82x | 2.56x |
| Eli Lilly and Company (LLY)vs › | $1.07T | 9.04x | 7.97x | 9.63x | 8.25x |
| Bristol-Myers Squibb Company (BMY)vs › | $116.66B | 1.75x | 1.55x | 1.56x | 1.64x |
Johnson & Johnson EV/Assets Ratio Formula & Definition
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Johnson & Johnson EV/Assets Ratio FAQ
- What is the EV/Assets ratio for Johnson & Johnson (JNJ)?
- The EV/Assets ratio for JNJ stock is 3.10x.
- Is Johnson & Johnson's EV/Assets ratio high or low?
- Johnson & Johnson's EV/Assets ratio of 3.10x is 25% above its 5-year average of 2.49x, near the high end of its 5-year range (1.90x–3.18x).
- What is the TTM average EV/Assets ratio for Johnson & Johnson (JNJ)?
- The TTM average EV/Assets ratio for JNJ stock is 2.68x.
- What is the 3Y average EV/Assets ratio for Johnson & Johnson (JNJ)?
- The 3Y average EV/Assets ratio for JNJ stock is 2.33x.
- What is the 5Y average EV/Assets ratio for Johnson & Johnson (JNJ)?
- The 5Y average EV/Assets ratio for JNJ stock is 2.49x.
- What is the 10Y average EV/Assets ratio for Johnson & Johnson (JNJ)?
- The 10Y average EV/Assets ratio for JNJ stock is 2.48x.
- What is the 15Y average EV/Assets ratio for Johnson & Johnson (JNJ)?
- The 15Y average EV/Assets ratio for JNJ stock is 2.34x.
- What is the 20Y average EV/Assets ratio for Johnson & Johnson (JNJ)?
- The 20Y average EV/Assets ratio for JNJ stock is 2.29x.
Johnson & Johnson EV/Assets Ratio History
| DATE | EV/ASSETS RATIO |
|---|---|
| 2026-06-12 | 3.10x |
| 2026-06-11 | 3.07x |
| 2026-06-10 | 3.07x |
| 2026-06-09 | 3.05x |
| 2026-06-08 | 2.99x |
| 2026-06-05 | 3.00x |
| 2026-06-04 | 2.94x |
| 2026-06-03 | 2.88x |
| 2026-06-02 | 2.88x |
| 2026-06-01 | 2.89x |
| 2026-05-29 | 2.91x |
| 2026-05-28 | 2.97x |
| 2026-05-27 | 2.98x |
| 2026-05-26 | 2.97x |
| 2026-05-22 | 3.02x |
| 2026-05-21 | 2.99x |
| 2026-05-20 | 2.96x |
| 2026-05-19 | 2.97x |
| 2026-05-18 | 2.95x |
| 2026-05-15 | 2.93x |
| 2026-05-14 | 2.97x |
| 2026-05-13 | 2.97x |
| 2026-05-12 | 2.90x |
| 2026-05-11 | 2.86x |
| 2026-05-08 | 2.86x |
| 2026-05-07 | 2.87x |
| 2026-05-06 | 2.90x |
| 2026-05-05 | 2.91x |
| 2026-05-04 | 2.89x |
| 2026-05-01 | 2.93x |
| 2026-04-30 | 2.96x |
| 2026-04-29 | 2.93x |
| 2026-04-28 | 2.94x |
| 2026-04-27 | 2.91x |
| 2026-04-24 | 2.93x |
| 2026-04-23 | 2.97x |
| 2026-04-22 | 2.92x |
| 2026-04-21 | 2.91x |
| 2026-04-20 | 2.97x |
| 2026-04-17 | 3.01x |
| 2026-04-16 | 3.01x |
| 2026-04-15 | 3.06x |
| 2026-04-14 | 3.08x |
| 2026-04-13 | 3.06x |
| 2026-04-10 | 3.06x |
| 2026-04-09 | 3.10x |
| 2026-04-08 | 3.10x |
| 2026-04-07 | 3.06x |
| 2026-04-06 | 3.09x |
| 2026-04-02 | 3.12x |
| 2026-04-01 | 3.13x |
| 2026-03-31 | 3.13x |
| 2026-03-30 | 3.11x |
| 2026-03-27 | 3.09x |
| 2026-03-26 | 3.07x |
| 2026-03-25 | 3.08x |
| 2026-03-24 | 3.02x |
| 2026-03-23 | 3.02x |
| 2026-03-20 | 3.02x |
| 2026-03-19 | 3.05x |
| 2026-03-18 | 3.05x |
| 2026-03-17 | 3.06x |
| 2026-03-16 | 3.12x |
| 2026-03-13 | 3.10x |
| 2026-03-12 | 3.11x |
| 2026-03-11 | 3.12x |
| 2026-03-10 | 3.13x |
| 2026-03-09 | 3.11x |
| 2026-03-06 | 3.08x |
| 2026-03-05 | 3.08x |
| 2026-03-04 | 3.14x |
| 2026-03-03 | 3.16x |
| 2026-03-02 | 3.18x |
| 2026-02-27 | 3.18x |
| 2026-02-26 | 3.12x |
| 2026-02-25 | 3.14x |
| 2026-02-24 | 3.16x |
| 2026-02-23 | 3.15x |
| 2026-02-20 | 3.11x |
| 2026-02-19 | 3.16x |
| 2026-02-18 | 3.14x |
| 2026-02-17 | 3.12x |
| 2026-02-13 | 3.12x |
| 2026-02-12 | 3.14x |
| 2026-02-11 | 3.09x |
| 2026-02-10 | 3.15x |
| 2026-02-09 | 3.15x |
| 2026-02-06 | 3.17x |
| 2026-02-05 | 3.14x |
| 2026-02-04 | 3.10x |
| 2026-02-03 | 3.08x |
| 2026-02-02 | 3.05x |
| 2026-01-30 | 3.01x |
| 2026-01-29 | 3.01x |
| 2026-01-28 | 3.01x |
| 2026-01-27 | 2.97x |
| 2026-01-26 | 2.93x |
| 2026-01-23 | 2.92x |
| 2026-01-22 | 2.89x |
| 2026-01-21 | 2.89x |
| 2026-01-20 | 2.89x |
| 2026-01-16 | 2.90x |
| 2026-01-15 | 2.91x |
| 2026-01-14 | 2.90x |
| 2026-01-13 | 2.83x |
| 2026-01-12 | 2.78x |
| 2026-01-09 | 2.72x |
| 2026-01-08 | 2.73x |
| 2026-01-07 | 2.76x |
| 2026-01-06 | 2.72x |
| 2026-01-05 | 2.72x |
| 2026-01-02 | 2.75x |
| 2025-12-31 | 2.75x |
| 2025-12-30 | 2.75x |
| 2025-12-29 | 2.76x |
| 2025-12-26 | 2.76x |
| 2025-12-24 | 2.76x |
| 2025-12-23 | 2.73x |
| 2025-12-22 | 2.75x |
| 2025-12-19 | 2.74x |
| 2025-12-18 | 2.77x |
| 2025-12-17 | 2.79x |
| 2025-12-16 | 2.78x |
| 2025-12-15 | 2.84x |
| 2025-12-12 | 2.81x |
| 2025-12-11 | 2.79x |
| 2025-12-10 | 2.74x |
| 2025-12-09 | 2.66x |
| 2025-12-08 | 2.68x |
| 2025-12-05 | 2.69x |
| 2025-12-04 | 2.69x |
| 2025-12-03 | 2.73x |
| 2025-12-02 | 2.73x |
| 2025-12-01 | 2.73x |
| 2025-11-28 | 2.75x |
| 2025-11-26 | 2.76x |
| 2025-11-25 | 2.75x |
| 2025-11-24 | 2.74x |
| 2025-11-21 | 2.71x |
| 2025-11-20 | 2.70x |
| 2025-11-19 | 2.69x |
| 2025-11-18 | 2.66x |
| 2025-11-17 | 2.66x |
| 2025-11-14 | 2.61x |
| 2025-11-13 | 2.60x |
| 2025-11-12 | 2.59x |
| 2025-11-11 | 2.58x |
| 2025-11-10 | 2.52x |
| 2025-11-07 | 2.49x |
| 2025-11-06 | 2.50x |
| 2025-11-05 | 2.49x |
| 2025-11-04 | 2.50x |
| 2025-11-03 | 2.49x |
| 2025-10-31 | 2.52x |
| 2025-10-30 | 2.52x |
| 2025-10-29 | 2.49x |
| 2025-10-28 | 2.50x |
| 2025-10-27 | 2.54x |
| 2025-10-24 | 2.54x |
| 2025-10-23 | 2.57x |
| 2025-10-22 | 2.57x |
| 2025-10-21 | 2.57x |
| 2025-10-20 | 2.59x |
| 2025-10-17 | 2.58x |
| 2025-10-16 | 2.57x |
| 2025-10-15 | 2.56x |
| 2025-10-14 | 2.55x |
| 2025-10-13 | 2.55x |
| 2025-10-10 | 2.55x |
| 2025-10-09 | 2.56x |
| 2025-10-08 | 2.54x |
| 2025-10-07 | 2.53x |
| 2025-10-06 | 2.52x |
| 2025-10-03 | 2.53x |
| 2025-10-02 | 2.49x |
| 2025-10-01 | 2.49x |
| 2025-09-30 | 2.49x |
| 2025-09-29 | 2.44x |
| 2025-09-26 | 2.41x |
| 2025-09-25 | 2.39x |
| 2025-09-24 | 2.38x |
| 2025-09-23 | 2.38x |
| 2025-09-22 | 2.35x |
| 2025-09-19 | 2.37x |
| 2025-09-18 | 2.34x |
| 2025-09-17 | 2.38x |
| 2025-09-16 | 2.37x |
| 2025-09-15 | 2.39x |
| 2025-09-12 | 2.39x |
| 2025-09-11 | 2.40x |
| 2025-09-10 | 2.37x |
| 2025-09-09 | 2.38x |
| 2025-09-08 | 2.39x |
| 2025-09-05 | 2.40x |
| 2025-09-04 | 2.40x |
| 2025-09-03 | 2.39x |
| 2025-09-02 | 2.39x |
| 2025-08-29 | 2.38x |
| 2025-08-28 | 2.36x |
| 2025-08-27 | 2.38x |
| 2025-08-26 | 2.37x |
| 2025-08-25 | 2.40x |
| 2025-08-22 | 2.41x |
| 2025-08-21 | 2.40x |
| 2025-08-20 | 2.40x |
| 2025-08-19 | 2.39x |
| 2025-08-18 | 2.37x |
| 2025-08-15 | 2.38x |
| 2025-08-14 | 2.35x |
| 2025-08-13 | 2.35x |
| 2025-08-12 | 2.33x |
| 2025-08-11 | 2.34x |
| 2025-08-08 | 2.33x |
| 2025-08-07 | 2.31x |
| 2025-08-06 | 2.30x |
| 2025-08-05 | 2.30x |
| 2025-08-04 | 2.31x |
| 2025-08-01 | 2.26x |
| 2025-07-31 | 2.23x |
| 2025-07-30 | 2.26x |
| 2025-07-29 | 2.27x |
| 2025-07-28 | 2.25x |
| 2025-07-25 | 2.27x |
| 2025-07-24 | 2.29x |
| 2025-07-23 | 2.19x |
| 2025-07-22 | 2.17x |
| 2025-07-21 | 2.13x |
| 2025-07-18 | 2.12x |
| 2025-07-17 | 2.11x |
| 2025-07-16 | 2.13x |
| 2025-07-15 | 2.01x |
| 2025-07-14 | 2.03x |
| 2025-07-11 | 2.03x |
| 2025-07-10 | 2.04x |
| 2025-07-09 | 2.03x |
| 2025-07-08 | 2.02x |
| 2025-07-07 | 2.01x |
| 2025-07-03 | 2.02x |
| 2025-07-02 | 2.02x |
| 2025-07-01 | 2.02x |
| 2025-06-30 | 1.98x |
| 2025-06-27 | 1.98x |
| 2025-06-26 | 1.97x |
| 2025-06-25 | 1.98x |
| 2025-06-24 | 1.98x |
| 2025-06-23 | 1.96x |
| 2025-06-20 | 1.95x |
| 2025-06-18 | 1.96x |
| 2025-06-17 | 1.98x |
| 2025-06-16 | 2.01x |
| 2025-06-13 | 2.04x |
| 2025-06-12 | 2.03x |
| 2025-06-11 | 2.01x |
| 2025-06-10 | 2.03x |
| 2025-06-09 | 2.01x |
| 2025-06-06 | 2.01x |
| 2025-06-05 | 1.99x |
| 2025-06-04 | 1.99x |
| 2025-06-03 | 2.00x |
| 2025-06-02 | 2.02x |
Showing the most recent 260 of 5,033 data points. The chart above shows the full history.
Related Metrics
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato